Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Treasury Shares (2019 - 2026)

Organogenesis Holdings has reported Treasury Shares over the past 7 years, most recently at $397800.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 91.22% year-over-year to $397800.0; the TTM value through Dec 2025 reached $397800.0, down 91.22%, while the annual FY2025 figure was $397800.0, 91.22% down from the prior year.
  • Treasury Shares for Q4 2025 was $397800.0 at Organogenesis Holdings, down from $4.8 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $4.8 million in Q1 2025 and troughed at $397800.0 in Q4 2025.
  • A 5-year average of $2.9 million and a median of $3.9 million in 2023 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: skyrocketed 182.28% in 2023 and later crashed 91.22% in 2025.
  • Year by year, Treasury Shares stood at $764871.0 in 2021, then soared by 80.62% to $1.4 million in 2022, then soared by 182.18% to $3.9 million in 2023, then increased by 16.19% to $4.5 million in 2024, then crashed by 91.22% to $397800.0 in 2025.
  • Business Quant data shows Treasury Shares for ORGO at $397800.0 in Q4 2025, $4.8 million in Q3 2025, and $4.8 million in Q2 2025.